Japan, Sept. 16 -- IONIS PHARMACEUTICALS INC has got intellectual property rights for 'MODULATORS OF DIACYLGLYCEROL ACYLTRANSFERASE 2 (DGAT2).' Other related details are as follows:
Application Number: JP,2022-062264
Category (FI): A61P1/16,A61P43/00,105,A61P3/06,A61K48/00,A61K47/54,A61K31/7088,C12N5/071,C12N15/113,130@Z
Stage: PROBLEM TO BE SOLVED: To provide compounds, compositions and methods for treating, preventing or ameliorating diseases associated with nonalcoholic fatty liver disease, including non-alcoholic steatohepatitis (NASH) and hepatic steatosis, by administering a diacylglycerol acyltransferase 2 (DGAT2) specific inhibitor to an individual.SOLUTION: Provided is a compound comprising a modified oligonucleotide of 8 to 80 linked nucleosides in length having a nucleobase comprising at least eight continuous nucleobases of any of a plurality of specific nucleobase sequences.SELECTED DRAWING: None (Grant)
Filing Date: April 4, 2022
Publication Date: July 20, 2022
The original document can be viewed at: https://www.j-platpat.inpit.go.jp/p0100
Disclaimer: Curated by HT Syndication.
